Original Article
Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome
N Engl J Med 2009; 361:345-357July 23, 2009
- Abstract
Background
The hemolytic–uremic syndrome consists of the triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. The common form of the syndrome is triggered by infection with Shiga toxin–producing bacteria and has a favorable outcome. The less common form of the syndrome, called atypical hemolytic–uremic syndrome, accounts for about 10% of cases, and patients with this form of the syndrome have a poor prognosis. Approximately half of the patients with atypical hemolytic–uremic syndrome have mutations in genes that regulate the complement system. Genetic factors in the remaining cases are unknown. We studied the role of thrombomodulin, an endothelial glycoprotein with anticoagulant, antiinflammatory, and cytoprotective properties, in atypical hemolytic–uremic syndrome.
Methods
We sequenced the entire thrombomodulin gene (THBD) in 152 patients with atypical hemolytic–uremic syndrome and in 380 controls. Using purified proteins and cell-expression systems, we investigated whether thrombomodulin regulates the complement system, and we characterized the mechanisms. We evaluated the effects of thrombomodulin missense mutations associated with atypical hemolytic–uremic syndrome on complement activation by expressing thrombomodulin variants in cultured cells.
Results
Of 152 patients with atypical hemolytic–uremic syndrome, 7 unrelated patients had six different heterozygous missense THBD mutations. In vitro, thrombomodulin binds to C3b and factor H (CFH) and negatively regulates complement by accelerating factor I–mediated inactivation of C3b in the presence of cofactors, CFH or C4b binding protein. By promoting activation of the plasma procarboxypeptidase B, thrombomodulin also accelerates the inactivation of anaphylatoxins C3a and C5a. Cultured cells expressing thrombomodulin variants associated with atypical hemolytic–uremic syndrome had diminished capacity to inactivate C3b and to activate procarboxypeptidase B and were thus less protected from activated complement.
Conclusions
Mutations that impair the function of thrombomodulin occur in about 5% of patients with atypical hemolytic–uremic syndrome.
Media in This Article
Figure 1
Alternative Pathway of Complement Activation and Regulation.Figure 2
Pedigrees of Patients with Familial Atypical Hemolytic–Uremic Syndrome.Article Activity
- Article
The hemolytic–uremic syndrome consists of the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. It is one of the thrombotic microangiopathies, along with thrombotic thrombocytopenia purpura and preeclampsia.1 The hemolytic–uremic syndrome is the most common cause of acute renal failure among children, a condition for which 50 to 75% of patients require dialysis.2 More than 85% of cases of the hemolytic–uremic syndrome are referred to as “typical”; these are preceded by diarrhea caused by strains of Escherichia coli 3-5 that produce Shiga-like toxins, which have proinflammatory and prothrombotic effects on the vascular endothelium.6 Most cases of typical hemolytic–uremic syndrome have a favorable outcome, although in approximately 25% of the patients, there is residual renal dysfunction. In contrast, the less common, “atypical,” form of the hemolytic–uremic syndrome is not linked to Shiga toxin–producing bacteria; it may be familial or sporadic, it often recurs, and it almost always follows an aggressive course. End-stage renal failure develops in 50% of patients with atypical hemolytic–uremic syndrome, and 25% of patients die as a result of the syndrome.7
An association between atypical hemolytic–uremic syndrome and uncontrolled complement activation has been established.8 Approximately 50% of patients have heterozygous loss-of-function mutations in genes encoding inhibitors of the alternative pathway of the complement system: factor H (CFH),9,10 factor I (CFI),11 membrane cofactor protein (MCP),12,13 CFH-related proteins (CFHR),14 and C4b binding protein (C4bBP).15 Gain-of-function mutations in genes encoding factor B (CFB)16 and C3,17 which promote alternative-pathway activation, have been reported in a few cases, and antibodies against CFH have been observed in 2 to 10% of patients14,18 (Figure 1Figure 1
Alternative Pathway of Complement Activation and Regulation., and see Glossary
Glossary. for explanation of complement components). The cause of atypical hemolytic–uremic syndrome in the remaining 50% of cases is unknown.Several lines of evidence point to a role of thrombomodulin in the pathogenesis of atypical hemolytic–uremic syndrome. Thrombomodulin is a ubiquitous transmembrane endothelial-cell glycoprotein. It accelerates thrombin-mediated activation of protein C,19 which down-regulates further thrombin generation, thereby suppressing clot formation. Activated protein C also has antiinflammatory and cytoprotective properties.20 Thrombomodulin enhances thrombin-mediated activation of plasma procarboxypeptidase B (thrombin activatable fibrinolysis inhibitor [TAFI]), an inhibitor of fibrinolysis21 that also inactivates complement-derived anaphylatoxins C3a and C5a.22-24 Thrombomodulin, through its lectin-like domain, interferes with inflammation by suppressing leukocyte trafficking and dampening complement activation.25,26
The strategic location of thrombomodulin throughout the vasculature and its role in regulating coagulation, innate immunity, and complement activation led us to hypothesize that variants of the gene encoding thrombomodulin (THBD) confer a predisposition to endothelial injury and microvascular thrombosis, which is manifested clinically as the atypical hemolytic–uremic syndrome. We identified six THBD variants in seven patients with atypical hemolytic–uremic syndrome. We also showed that thrombomodulin is a negative regulator of the complement system and that thrombomodulin mutations associated with atypical hemolytic–uremic syndrome cause defective complement regulation.
Methods
Patients
We recruited for this study 152 consecutive patients with atypical hemolytic–uremic syndrome from the International Registry of Recurrent and Familial HUS/TTP.27 A diagnosis of atypical hemolytic–uremic syndrome was made in patients who had one or more episodes of microangiopathic hemolytic anemia and thrombocytopenia associated with acute renal failure.28 Patients in whom the hemolytic–uremic syndrome was associated with Shiga toxin–producing bacteria were excluded. Healthy controls, unrelated to each other or to the patients, were matched according to sex and geographic origin. Details of the diagnostic criteria and participant selection are provided in the Methods section in the Supplementary Appendix, available with the full text of this article at NEJM.org.
We screened these 152 patients for mutations in CFH, MCP, CFI, and THBD. Patients with THBD mutations were also screened for CFB and C3 mutations. Since functional abnormalities in the von Willebrand factor–cleaving metalloproteinase, ADAMTS13, have been associated with atypical hemolytic–uremic syndrome, we also measured its activity with the use of a collagen-binding assay when possible.29 The study was approved by the bioethics committee of the Province of Bergamo, Italy. Participants or their legal guardians provided written informed consent.
Study Assessments
The sequencing methods and in vitro assays that were used to measure the effects of purified thrombomodulin or cell-surface thrombomodulin on the generation and deposition of C3b proteolytic fragments and on thrombin-mediated activation of TAFI are described in the Methods section in the Supplementary Appendix. A description of the statistical analyses is also included in the Supplementary Appendix.
Results
THBD Single-Nucleotide Polymorphisms
We sequenced bidirectionally the entire coding region of the THBD gene (which lacks introns) in 380 controls and 152 patients with atypical hemolytic–uremic syndrome: 31 patients with CFH mutations (20.4%), 1 with anti-CFH antibodies (0.7%), 10 with MCP mutations (6.6%), and 5 with CFI mutations (3.3%). Six amino acid–changing, heterozygous mutations of THBD were identified in seven unrelated patients (4.6%); none of these mutations were found in the controls. None of the 380 controls had any synonymous or nonsynonymous single-nucleotide polymorphisms (SNPs) within the coding region, with the exception of a known common THBD coding SNP (rs1042579), a C→T change at base 1418, leading to replacement of alanine 473 by valine (A473V).30 Genotyping was confirmed with the use of the Sequenom MassARRAY system31; this system was also used to determine the frequency of A473V and the other known THBD variants (including those within the 5′ and 3′ untranslated regions) in 268 additional healthy subjects (see details of genotyping and SNP analyses in the Methods section in the Supplementary Appendix). The allele frequencies of the A473V SNP did not differ significantly between patients with atypical hemolytic–uremic syndrome and controls (P=0.93). This was also the case for six common SNPs in the 5′ and 3′ untranslated regions of THBD (rs1040585, rs2424505, rs6076016, rs1042580, rs3176123, and rs1962) (Table 1 in the Supplementary Appendix). Clinical data and pedigrees of mutation carriers are provided in Table 1Table 1
Characteristics of Patients with Atypical Hemolytic–Uremic Syndrome and Thrombomodulin Gene Mutations. and Figure 2Figure 2Pedigrees of Patients with Familial Atypical Hemolytic–Uremic Syndrome. and in the case reports in the Supplementary Appendix.Three patients (two with a family history of atypical hemolytic–uremic syndrome [Patients F635 and F163] and one with sporadic atypical hemolytic–uremic syndrome [Patient S884]) were heterozygous for mutations that cause amino acid changes in the lectin-like domain of thrombomodulin (A43T in Patient F635, D53G in Patient F163, and V81L in Patient S884).
Patient F635 had had several episodes of the hemolytic–uremic syndrome in infancy, leading to chronic renal failure. He had eight siblings, three of whom had died during acute episodes of the hemolytic–uremic syndrome. A sister (Patient F961), who also carried the A43T mutation, had had one episode of the hemolytic–uremic syndrome during infancy. The mother (Patient F962) and another sibling (Patient F964) were also heterozygous carriers, but neither they nor the other siblings had symptoms or signs of the hemolytic–uremic syndrome (Pedigree 185 in Figure 2).
In Pedigree 008 (Figure 2), the unaffected brother and mother of Patient F163 carried the D53G mutation, whereas the father did not. The deceased sibling was not tested.
Four additional patients with sporadic atypical hemolytic–uremic syndrome (Patients S511, S015, S665, and S924) had missense mutations in the serine–threonine-rich region of thrombomodulin (P495S in Patient S511, P501L in Patient S015, and D486Y in Patients S665 and S924, who were not related to each other).
In the case of all carriers of the thrombomodulin mutation, the disease was evident during childhood, and in two patients (F163 and S884), it was preceded by a viruslike illness. No patient carried a concurrent mutation in CFH, MCP, CFI, CFB, or C3, nor did any of them have anti-CFH autoantibodies. ADAMTS13 activity was normal in Patients S015, S884, F163, and S703. Four of the patients with thrombomodulin mutations (F635, F163, S884, and S511) had low serum C3 levels. C4 levels were normal in all the patients. These findings suggest that thrombomodulin mutations are associated with excess activation of the alternative complement pathway.9
Thrombomodulin and Complement Activation
To test whether genetic variations of THBD contribute to the activation of complement, we examined the ability of wild-type and mutant thrombomodulin to provide protection against complement activation on the cell surface.32-34 CHO-K1 cells were stably transfected with empty vector (control) or with vector expressing thrombomodulin. Complement activation was induced by incubating cells with complement-fixing anti-CHO antibodies, followed by C6-depleted serum. Staining of total C3b plus inactivated C3b (iC3b) (with an anti-C3c antibody that recognizes both C3b and iC3b) and of iC3b alone (with a specific anti-iC3b antibody) was quantified by flow cytometry. The expression of wild-type thrombomodulin, as compared with the control vector, resulted in an increase by a median factor of 2.6 (range 2.4 to 2.7) in the percentage of C3b that was cleaved to iC3b on the cell surface, as calculated by the ratio of iC3b to (C3b+iC3b) on staining (Figure 3AFigure 3
Effect of Mutations Associated with Atypical Hemolytic–Uremic Syndrome on the Ability of Thrombomodulin to Enhance Complement Inactivation.). This indicates that thrombomodulin provides protection against complement activation.As compared with CHO-K1 cells that were transfected with wild-type thrombomodulin, all cells that were transfected with the other thrombomodulin variants were less effective in converting C3b to iC3b on the cell surface after immune-complex–initiated complement activation (Figure 3A).
Thrombomodulin and C3b and CFH
Inactivation of surface-bound C3b depends on the binding of CFH to heparan sulfate molecules and C3b. CFH mutations associated with atypical hemolytic–uremic syndrome disrupt such binding to endothelial cells, diminishing the capacity of CFH to suppress complement activation.35 Since thrombomodulin is present on the surface of all endothelial cells, we tested whether it interacts with CFH and facilitates CFI-mediated C3b cleavage to yield iC3b. Coprecipitation studies showed specific CFH and C3b binding to thrombomodulin (Figure 3B and 3C).
After immobilizing cell-membrane preparations of HEK293 cells expressing wild-type thrombomodulin or the thrombomodulin variants associated with atypical hemolytic–uremic syndrome, we measured the binding of biotinylated CFH or C3b with the use of an enzyme-linked immunosorbent assay. Surprisingly, the binding of CFH and C3b to all the thrombomodulin variants, except D486Y, was significantly increased, as compared with the binding to wild-type thrombomodulin (Figure 3D).
Thrombomodulin and C3b Inactivation
We next tested whether the enhanced binding to the thrombomodulin variants was associated with alterations in the functional relationship of these proteins. The activity of thrombomodulin in complement regulation in solution was tested by incubating recombinant thrombomodulin with combinations of C3b, CFI, and either CFH or C4bBP (CFI cofactors) (Figure 4Figure 4
Inactivation of Complement Factor C3b by Complement Factor I, as Facilitated by Thrombomodulin.). Thrombomodulin enhanced CFI-mediated inactivation of C3b in a dose-dependent manner in the presence of either CFH or C4bBP (Figure 4B and 4C). As expected, there was no C3b cleavage by CFI in the absence of a cofactor (data not shown).The effect of thrombomodulin mutations associated with the atypical hemolytic–uremic syndrome on the capacity of thrombomodulin to enhance CFI-mediated inactivation of C3b was evaluated on the surface of a series of HEK293 cells that expressed each of the variants in equal amounts. In the presence of CFH, thrombomodulin variants were less effective than wild-type thrombomodulin in enhancing CFI-mediated conversion of C3b to iC3b (Figure 5AFigure 5
Effect of Thrombomodulin Mutations Associated with Atypical Hemolytic–Uremic Syndrome on Inactivation of Complement Factor C3b and on Activation of Plasma Procarboxypeptidase B (TAFI).). Diminished CFI-mediated inactivation of C3b in the presence of C4bBP was apparent only with the P501L mutation (Figure 5B), a finding that is consistent with the predominance of CFH as a CFI cofactor.Thrombomodulin Mutations and TAFI
Thrombomodulin also supports thrombin-mediated conversion of TAFI to activated TAFI (TAFIa), low levels of which have been associated with the hemolytic–uremic syndrome.36 We tested the effect of the thrombomodulin variants on thrombin-mediated generation of TAFIa, as assessed by the appearance of a 36-kD fragment37 (Figure 5C). We found that generation of TAFIa was significantly reduced with all the variants associated with atypical hemolytic–uremic syndrome, as compared with wild-type thrombomodulin.
Discussion
We identified six missense mutations in the gene encoding thrombomodulin in seven unrelated patients with atypical hemolytic–uremic syndrome, accounting for 4.6% of the 152 cases. We also found that the resultant thrombomodulin variants did not protect cultured cells against complement activation. SNPs in the coding region of the THBD gene are rare,38-40 and only eight missense changes are reported in the dbSNP database (www.ncbi.nlm.nih.gov/projects/SNP). One insertion frameshift mutation has been described in a kindred with myocardial infarction,41 whereas no homozygous mutations have been reported. All the THBD gene mutations that we identified were heterozygous.
In one carrier of a mutation, the disease was first manifested when the person was 15 years of age, and in four carriers, the hemolytic–uremic syndrome has not developed. These data suggest that mutation of a single THBD allele is not sufficient by itself to cause atypical hemolytic–uremic syndrome. Rather, additional factors — environmental, genetic, or epigenetic — are probably required. Indeed, in two patients, episodes of the hemolytic–uremic syndrome were triggered by viruslike illnesses. This finding is relevant to thrombomodulin, since the expression of thrombomodulin is down-regulated during inflammation and infection.42-45 Overall, the findings are similar to those observed with mutations in CFH, CFI, C3, C4bBP, and CFB in the hemolytic–uremic syndrome, which are often missense mutations (in the case of CFH, CFI and C3)17,27 and are usually heterozygous4,9-13,15-17 and associated with disease after an infection.27
Thrombomodulin is a 557-amino-acid endothelial glycoprotein that is anchored to the cell by a short cytoplasmic tail and a single transmembrane domain.46 A series of six epidermal growth-factor–like repeats are required for thrombin-mediated generation of activated protein C, which has anticoagulant and cytoprotective properties, and the generation of activated TAFI, which has C3a-degrading and C5a-degrading properties.23,47,48 Farthest from the transmembrane domain is the lectinlike domain, which confers resistance to proinflammatory stimuli, including endotoxin and ischemia–reperfusion.25,49 It is notable that three of the missense mutations that we found to be associated with atypical hemolytic–uremic syndrome are in the lectinlike domain of thrombomodulin.
The A43T mutation is a rare variant that has been associated with venous thrombosis,50 atherosclerosis, and myocardial infarction.51 A computer-generated model of the lectinlike domain of thrombomodulin predicts that A43 is positioned on the surface of the molecule, where it could potentially bind to proteins in the circulation.52 This observation is in line with our findings that thrombomodulin variants associated with the atypical hemolytic–uremic syndrome that involve the lectinlike domain alter CFH and C3b binding and, in turn, the regulation of complement activation.
The other three mutations in sporadic cases of atypical hemolytic–uremic syndrome — D486Y, P495S, and P501L — reside in the serine–threonine-rich region of thrombomodulin. D486Y and P501L have been reported rarely in patients with venous thrombosis.53 These mutations are near the consensus sequence for attachment of chondroitin sulfate at serine 49254; in vitro, P495S and P501L moderately reduce expression of thrombomodulin on the cell surface, and P495S decreases the affinity of thrombomodulin for thrombin.55 All three of these variants exhibited defects in suppressing activation of the alternative complement pathway through CFI-mediated C3b inactivation in vitro, implicating them in the pathogenesis of atypical hemolytic–uremic syndrome. The additional impairment in TAFIa generation probably aggravates the disease.36 Thrombomodulin has a binding site for C3b and CFH, thereby accelerating CFI-mediated inactivation of C3b. Beyond these activities, which negatively regulate the alternative pathway, thrombomodulin plays a wider role in suppressing complement-mediated cell injury. Thrombomodulin interferes with thrombin-mediated activation of C556 and is necessary for thrombin-mediated generation of TAFIa. Thus, in addition to its role in coagulation, thrombomodulin interacts with several complement pathways (Figure 1).
Despite advances in delineating the pathogenesis of atypical hemolytic–uremic syndrome, effective therapies are lacking, and in most patients, end-stage renal failure requiring dialysis develops. Since thrombomodulin simultaneously suppresses the complement and coagulation systems, its administration may have therapeutic value for some patients with the atypical hemolytic–uremic syndrome. The efficacy and safety of recombinant thrombomodulin for disseminated intravascular coagulation have been shown in a phase 3 clinical trial.57
In conclusion, we have shown that thrombomodulin is a negative regulator of the complement system and that mutant variants of thrombomodulin may contribute to the development of atypical hemolytic–uremic syndrome.
Supported by a grant from the National Institutes of Health (DK71221), Istituto Superiore della Sanità (Project no. 526D/9), Fondazione ART Per La Ricerca Sui Trapianti (Milan) (all to Drs. Noris and Remuzzi), Fonds voor Wetenschappelijk Onderzoek (FWO #G.0675.08, to Dr. Conway), and Fondation Leducq in Paris (to Drs. C.T. Esmon and N.L. Esmon).
Drs. C.T. Esmon and N.L. Esmon report holding licenses and patents related to protein C and activated protein C that are unrelated to this article; and Dr. Conway, holding a patent for the use of the lectinlike domain of thrombomodulin as an antiinflammatory agent. No other potential conflict of interest relevant to this article was reported.
We thank the clinicians and patients for their membership in and support of the International Registry of Recurrent and Familial HUS/TTP (for a full list of the coordinators and investigators of the registry, see the Supplementary Appendix), with particular thanks to Dr. Kenneth Lieberman, Mrs. Rachel Dominguez, Dr. Avi Katz, Prof. Clifford E. Kashtan, Prof. Francesco Emma, and Dr. Rosa Bellantuono; Drs. Elena Bresin, Chiara Mossali, and Gaia Pianetti (Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy) for collecting clinical data and biologic samples for sequencing of complement genes; and the personnel of the VIB Genetic Service Facility for generating THBD sequences.
Source Information
From the VIB-K.U.Leuven Vesalius Research Center, Leuven (M.D., A.D.V., B.C., D.L., E.M.C.); VIB-University of Antwerp Applied Molecular Genomics Group, Department of Molecular Genetics, Antwerp (J.D.-F.); and VIB BioInformatics Training and Service Facility, Ghent (S.P.) — all in Belgium; Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Ranica, Bergamo, Italy (M.N., C.Z., G.R.); and the Oklahoma Medical Research Foundation (C.T.E., N.L.E.) and Howard Hughes Medical Institute (C.T.E., G.F.) — both in Oklahoma City.
Address reprint requests to Dr. Conway at the Centre for Blood Research, Life Sciences Centre, 2350 Health Sciences Mall, University of British Columbia, Vancouver, BC V6T 1Z3, Canada, or at emconway@interchange.ubc.ca.
- References
References
1
Zheng XL ,Sadler JE . Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008;3:249-277
CrossRef | Web of Science | Medline2
Constantinescu AR ,Bitzan M ,Weiss LS , et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004;43:976-982
CrossRef | Web of Science | Medline3
Moake JL . Thrombotic microangiopathies. N Engl J Med 2002;347:589-600
Full Text | Web of Science | Medline4
Noris M ,Remuzzi G . Hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:1035-1050
CrossRef | Web of Science | Medline5
Razzaq S . Hemolytic uremic syndrome: an emerging health risk. Am Fam Physician 2006;74:991-996
Web of Science | Medline6
Morigi M ,Galbusera M ,Binda E , et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 2001;98:1828-1835
CrossRef | Web of Science | Medline7
Kavanagh D ,Goodship TH ,Richards A . Atypical haemolytic uraemic syndrome. Br Med Bull 2006;77:5-22
CrossRef | Web of Science | Medline8
Jokiranta TS ,Zipfel PF ,Fremeaux-Bacchi V ,Taylor CM ,Goodship TJ ,Noris M . Where next with atypical hemolytic uremic syndrome? Mol Immunol 2007;44:3889-3900
CrossRef | Web of Science | Medline9
Caprioli J ,Bettinaglio P ,Zipfel PF , et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001;12:297-307
Web of Science | Medline10
Perez-Caballero D ,Gonzalez-Rubio C ,Gallardo ME , et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001;68:478-484
CrossRef | Web of Science | Medline11
Kavanagh D ,Richards A ,Noris M , et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008;45:95-105
CrossRef | Web of Science | Medline12
Fremeaux-Bacchi V ,Kemp EJ ,Goodship JA , et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet 2005;42:852-856
CrossRef | Web of Science | Medline13
Monteferrante G ,Brioschi S ,Caprioli J , et al. Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. Mol Immunol 2007;44:1704-1708
CrossRef | Web of Science | Medline14
Zipfel PF ,Edey M ,Heinen S , et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007;3:e41-e41
CrossRef | Web of Science | Medline15
Blom AM ,Bergstrom F ,Edey M , et al. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol 2008;180:6385-6391
Web of Science | Medline16
Goicoechea de Jorge E ,Harris CL ,Esparza-Gordillo J , et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007;104:240-245
CrossRef | Web of Science | Medline17
Fremeaux-Bacchi V ,Miller E ,Liszewski MK , et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008;112:4948-4952
CrossRef | Web of Science | Medline18
Jozsi M ,Licht C ,Strobel S , et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008;111:1512-1514
CrossRef | Web of Science | Medline19
Esmon C . Do-all receptor takes on coagulation, inflammation. Nat Med 2005;11:475-477
CrossRef | Web of Science | Medline20
Bernard GR ,Vincent JL ,Laterre PF , et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
Full Text | Web of Science | Medline21
Bajzar L ,Manuel R ,Nesheim M . Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14484
CrossRef | Web of Science | Medline22
Campbell WD ,Lazoura E ,Okada N ,Okada H . Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002;46:131-134
Web of Science | Medline23
Myles T ,Nishimura T ,Yun TH , et al. Thrombin activatable fibrinolysis inhibitor: a potential regulator of vascular inflammation. J Biol Chem 2003;278:51059-51067
CrossRef | Web of Science | Medline24
Nishimura T ,Myles T ,Piliponsky AM ,Kao PN ,Berry GJ ,Leung LL . Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood 2007;109:1992-1997
CrossRef | Web of Science | Medline25
Conway EM ,Van de Wouwer M ,Pollefeyt S , et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002;196:565-577
CrossRef | Web of Science | Medline26
Van de Wouwer M ,Plaisance S ,De Vriese A , et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006;4:1813-1824
CrossRef | Web of Science | Medline27
Caprioli J ,Noris M ,Brioschi S , et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108:1267-1279
CrossRef | Web of Science | Medline28
Bellomo R ,Ronco C ,Kellum JA ,Mehta RL ,Palevsky P . Acute renal failure -- definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-R212
CrossRef | Web of Science | Medline29
Remuzzi G ,Galbusera M ,Noris M , et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002;100:778-785
CrossRef | Web of Science | Medline30
Wu KK ,Aleksic N ,Ahn C ,Boerwinkle E ,Folsom AR ,Juneja H . Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease. Circulation 2001;103:1386-1389
CrossRef | Web of Science | Medline31
van den Boom D ,Ehrich M . Discovery and identification of sequence polymorphisms and mutations with MALDI-TOF MS. Methods Mol Biol 2007;366:287-306
CrossRef | Medline32
Barilla-LaBarca ML ,Liszewski MK ,Lambris JD ,Hourcade D ,Atkinson JP . Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J Immunol 2002;168:6298-6304
Web of Science | Medline33
Liszewski MK ,Atkinson JP . Membrane cofactor protein (MCP; CD46): isoforms differ in protection against the classical pathway of complement. J Immunol 1996;156:4415-4421
Web of Science | Medline34
Liszewski MK ,Leung MK ,Schraml B ,Goodship TH ,Atkinson JP . Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol 2007;44:1559-1568
CrossRef | Web of Science | Medline35
Manuelian T ,Hellwage J ,Meri S , et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003;111:1181-1190
CrossRef | Web of Science | Medline36
Sucker C ,Hetzel GR ,Farokhzad F , et al. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies -- a pilot study. Nephrol Dial Transplant 2007;22:1347-1350
CrossRef | Web of Science | Medline37
Buelens K ,Hillmayer K ,Compernolle G ,Declerck PJ ,Gils A . Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor. Circ Res 2008;102:295-301
CrossRef | Web of Science | Medline38
Faioni EM ,Franchi F ,Castaman G ,Biguzzi E ,Rodeghiero F . Mutations in the thrombomodulin gene are rare in patients with severe thrombophilia. Br J Haematol 2002;118:595-599
CrossRef | Web of Science | Medline39
Heit JA ,Petterson TM ,Owen WG ,Burke JP ,de Andrade M ,Melton LJ III . Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism: a population-based case-control study. J Thromb Haemost 2005;3:710-717
CrossRef | Web of Science | Medline40
Kaare M ,Ulander VM ,Painter JN ,Ahvenainen T ,Kaaja R ,Aittomaki K . Variations in the thrombomodulin and endothelial protein C receptor genes in couples with recurrent miscarriage. Hum Reprod 2007;22:864-868
CrossRef | Web of Science | Medline41
Kunz G ,Ireland HA ,Stubbs PJ ,Kahan M ,Coulton GC ,Lane DA . Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction. Blood 2000;95:569-576
Web of Science | Medline42
Taylor FB Jr . Studies on the inflammatory-coagulant axis in the baboon response to E. coli: regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor. Prog Clin Biol Res 1994;388:175-194
Medline43
Van de Wouwer M ,Collen D ,Conway EM . Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004;24:1374-1383
CrossRef | Web of Science | Medline44
Faust SN ,Levin M ,Harrison OB , et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-416
Full Text | Web of Science | Medline45
Vercellotti GM . Effects of viral activation of the vessel wall on inflammation and thrombosis. Blood Coagul Fibrinolysis 1998;9:Suppl 2:S3-S6
Web of Science | Medline46
Weiler H ,Isermann BH . Thrombomodulin. J Thromb Haemost 2003;1:1515-1524
CrossRef | Web of Science | Medline47
Weiler-Guettler H ,Christie PD ,Beeler DL , et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998;101:1983-1991
CrossRef | Web of Science | Medline48
Weiler H ,Lindner V ,Kerlin B , et al. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol 2001;21:1531-1537
CrossRef | Web of Science | Medline49
Geudens N ,Van de Wouwer M ,Vanaudenaerde B , et al. The lectin-like domain of thrombomodulin protects against ischemia-reperfusion lung injury. Eur Respir J 2008;32:862-870
CrossRef | Web of Science | Medline50
Norlund L ,Zoller B ,Ohlin A-K . A novel thrombomodulin gene mutation in a patient suffering from sagittal sinus thrombosis. Thromb Haemost 1997;78:1164-1166
Web of Science | Medline51
Doggen CJ ,Kunz G ,Rosendaal FR , et al. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost 1998;80:743-748
Web of Science | Medline52
Villoutreix B ,Dahlback B . Molecular model for the C-type lectin domain of human thrombomodulin. J Mol Model 1998;4:310-322
CrossRef | Web of Science53
Ohlin AK ,Marlar RA . Thrombomodulin gene defects in families with thromboembolic disease -- a report on four families. Thromb Haemost 1999;81:338-344
Web of Science | Medline54
Gerlitz B ,Hassell T ,Vlahos CJ ,Parkinson JF ,Bang NU ,Grinnell BW . Identification of the predominant glycosaminoglycan-attachment site in soluble recombinant human thrombomodulin: potential regulation of functionality by glycosyltransferase competition for serine474. Biochem J 1993;295:131-140
Web of Science | Medline55
Kunz G ,Ohlin AK ,Adami A ,Zoller B ,Svensson P ,Lane DA . Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and function. Blood 2002;99:3646-3653
CrossRef | Web of Science | Medline56
Huber-Lang M ,Sarma JV ,Zetoune FS , et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006;12:682-687
CrossRef | Web of Science | Medline57
Saito H ,Maruyama I ,Shimazaki S , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41
CrossRef | Web of Science | Medline
- Citing Articles (65)
Citing Articles
1
Sally Johnson, Aoife Waters. (2012) Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome?. Immunobiology 217:2, 235-243
CrossRef2
Heather Kerr, Anna Richards. (2012) Complement-mediated injury and protection of endothelium: Lessons from atypical haemolytic uraemic syndrome. Immunobiology 217:2, 195-203
CrossRef3
Luca Ermini, Timothy H.J. Goodship, Lisa Strain, Michael E. Weale, Steven H. Sacks, Heather J. Cordell, Veronique Fremeaux-Bacchi, Neil S. Sheerin. (2012) Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Molecular Immunology 49:4, 640-648
CrossRef4
Dana Provaznikova, Simon Rittich, Michal Malina, Tomas Seeman, Iuri Marinov, Magdalena Riedl, Ingrid Hrachovinova. (2012) Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. Pediatric Nephrology 27:1, 73-81
CrossRef5
Victor W. M. van Hinsbergh. (2012) Endothelium—role in regulation of coagulation and inflammation. Seminars in Immunopathology 34:1, 93-106
CrossRef6
Edward M. Conway. (2012) Thrombomodulin and its role in inflammation. Seminars in Immunopathology 34:1, 107-125
CrossRef7
Georgia Anastasiou, Argyri Gialeraki, Efrossyni Merkouri, Marianna Politou, Anthi Travlou. (2012) Thrombomodulin as a regulator of the anticoagulant pathway. Blood Coagulation & Fibrinolysis 23:1, 1-10
CrossRef8
Michal Malina, Lubka T. Roumenina, Tomáš Seeman, Moglie Le Quintrec, Marie-Agnes Dragon-Durey, Franz Schaefer, Véronique Fremeaux-Bacchi. (2012) Genetics of hemolytic uremic syndromes. La Presse Médicale
CrossRef9
Chantal Loirat, Jeffrey Saland, Martin Bitzan. (2012) Management of hemolytic uremic syndrome. La Presse Médicale
CrossRef10
Marina Noris, Giuseppe Remuzzi. 2012. Thrombotic microangiopathies. , 278-282.
CrossRef11
D. Kavanagh, T. H. J. Goodship. (2011) Atypical Hemolytic Uremic Syndrome, Genetic Basis, and Clinical Manifestations. Hematology 2011:1, 15-20
CrossRef12
M. K. Liszewski, J. P. Atkinson. (2011) Too Much of a Good Thing at the Site of Tissue Injury: The Instructive Example of the Complement System Predisposing to Thrombotic Microangiopathy. Hematology 2011:1, 9-14
CrossRef13
Maren Sullivan, Lisa A. Rybicki, Aurelia Winter, Michael M Hoffmann, Stefanie Reiermann, Hannah Linke, Klaus Arbeiter, Ludwig Patzer, Klemens Budde, Bernd Hoppe, Martin Zeier, Karl Lhotta, Andreas Bock, Thorsten Wiech, Ariana Gaspert, Thomas Fehr, Magdalena Woznowski, Gani Berisha, Angelica Malinoc, Oemer-Necmi Goek, Charis Eng, Hartmut PH Neumann. (2011) Age-Related Penetrance of Hereditary Atypical Hemolytic Uremic Syndrome. Annals of Human Genetics 75:6, 639-647
CrossRef14
Peter F. Zipfel, Gunter Wolf, Ulrike John, Karim Kentouche, Christine Skerka. (2011) Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?. Pediatric Nephrology 26:11, 1947-1956
CrossRef15
Saki Mukai, Yoshihiko Hidaka, Masako Hirota-Kawadobora, Kazuyuki Matsuda, Noriko Fujihara, Yuka Takezawa, Seiko Kubota, Kenichi Koike, Takayuki Honda, Kazuyoshi Yamauchi. (2011) Factor H gene variants in Japanese: Its relation to atypical hemolytic uremic syndrome. Molecular Immunology 49:1-2, 48-55
CrossRef16
A. R. Koskinen, E. Tukiainen, J. Arola, A. Nordin, H. K. Höckerstedt, B. Nilsson, H. Isoniemi, T. S. Jokiranta. (2011) Complement Activation During Liver Transplantation-Special Emphasis on Patients With Atypical Hemolytic Uremic Syndrome. American Journal of Transplantation 11:9, 1885-1895
CrossRef17
S. Lovric, J. T. Kielstein, D. Kayser, V. Brocker, J. U. Becker, M. Hiss, M. Schiffer, U. Sommerwerck, H. Haller, M. Struber, T. Welte, J. Gottlieb. (2011) Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series. Nephrology Dialysis Transplantation 26:9, 3032-3038
CrossRef18
M. Riedl, C. Licht. (2011) Hämolytisch-urämisches Syndrom und membranoproliferative Glomerulonephritis. Der Nephrologe 6:4, 355-364
CrossRef19
C. T. ESMON, J. XU, F. LUPU. (2011) Innate immunity and coagulation. Journal of Thrombosis and Haemostasis 9, 182-188
CrossRef20
T. ITO, I. MARUYAMA. (2011) Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. Journal of Thrombosis and Haemostasis 9, 168-173
CrossRef21
Matthew Pickering, H Terence Cook. (2011) Complement and glomerular disease: new insights. Current Opinion in Nephrology and Hypertension 20:3, 271-277
CrossRef22
Samhar I. Al-Akash, P. Stephen Almond, Van H. Savell, Salam I. Gharaybeh, Cris Hogue. (2011) Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatric Nephrology 26:4, 613-619
CrossRef23
Lindsay Keir, Richard J. M. Coward. (2011) Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatric Nephrology 26:4, 523-533
CrossRef24
Charles T. Esmon, Naomi L. Esmon. (2011) The Link Between Vascular Features and Thrombosis. Annual Review of Physiology 73:1, 503-514
CrossRef25
L Schejbel, I M Schmidt, M Kirchhoff, C B Andersen, H V Marquart, P Zipfel, P Garred. (2011) Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation. Genes and Immunity 12:2, 90-99
CrossRef26
Lubka T. Roumenina, Chantal Loirat, Marie-Agnes Dragon-Durey, Lise Halbwachs-Mecarelli, Catherine Sautes-Fridman, Veronique Fremeaux-Bacchi. (2011) Alternative complement pathway assessment in patients with atypical HUS. Journal of Immunological Methods 365:1-2, 8-26
CrossRef27
Steven P LaRosa, Steven M Opal. (2011) Strategies to treat sepsis: old and new. Clinical Investigation 1:2, 195-210
CrossRef28
Julien Zuber, Moglie Le Quintrec, Rebecca Sberro-Soussan, Chantal Loirat, Véronique Frémeaux-Bacchi, Christophe Legendre. (2011) New insights into postrenal transplant hemolytic uremic syndrome. Nature Reviews Nephrology 7:1, 23-35
CrossRef29
Chantal Loirat, Véronique Frémeaux-Bacchi. (2011) Atypical hemolytic uremic syndrome. Orphanet Journal of Rare Diseases 6:1, 60
CrossRef30
Kazuma Yamakawa, Satoshi Fujimi, Tomoyoshi Mohri, Hiroki Matsuda, Yasushi Nakamori, Tomoya Hirose, Osamu Tasaki, Hiroshi Ogura, Yasuyuki Kuwagata, Toshimitsu Hamasaki, Takeshi Shimazu. (2011) Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Critical Care 15:3, R123
CrossRef31
Aoife M. Waters, Christoph Licht. (2011) aHUS caused by complement dysregulation: new therapies on the horizon. Pediatric Nephrology 26:1, 41-57
CrossRef32
Olivia Boyer, Patrick Niaudet. (2011) Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment. International Journal of Nephrology 2011, 1-10
CrossRef33
D Provan, AC Newland, PK MacCallum. 2011. Acquired disorders affecting megakaryocytes and platelets. , 523-545.
CrossRef34
David Kavanagh, Tim Goodship. (2010) Genetics and complement in atypical HUS. Pediatric Nephrology 25:12, 2431-2442
CrossRef35
Ryan J. Goldberg, Takahiko Nakagawa, Richard J. Johnson, Joshua M. Thurman. (2010) The Role of Endothelial Cell Injury in Thrombotic Microangiopathy. American Journal of Kidney Diseases 56:6, 1168-1174
CrossRef36
Alessandro Bucalossi, Francesca Toraldo, Monica Tozzi, Mariapia Lenoci, Cinzia Castagnini, Rosangela Artuso, Alessandra Renieri, Giuseppe Marotta. (2010) Is Complement Alternative Pathway Disregulation Involved in Veno-Occlusive Disease of the Liver?. Biology of Blood and Marrow Transplantation 16:12, 1749-1750
CrossRef37
K. Amann, K. Benz. (2010) Thrombotische Mikroangiopathie (TMA): neue Aspekte. Der Nephrologe 5:6, 473-482
CrossRef38
Vera Eremina, Susan E. Quaggin. (2010) Biology of Anti-Angiogenic Therapy–Induced Thrombotic Microangiopathy. Seminars in Nephrology 30:6, 582-590
CrossRef39
ALLISON M LESHER, WEN-CHAO SONG. (2010) Review: Complement and its regulatory proteins in kidney diseases. Nephrology 15:7, 663-675
CrossRef40
E Goicoechea de Jorge, Matthew C Pickering. (2010) Atypical hemolytic uremic syndrome: telling the difference between H and Y. Kidney International 78:8, 721-723
CrossRef41
, Peter F. Zipfel, Christoph Mache, Dominik Müller, Christoph Licht, Marianne Wigger, Christine Skerka. (2010) DEAP-HUS: Deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatric Nephrology 25:10, 2009-2019
CrossRef42
Pilar Sánchez-Corral, Marta Melgosa. (2010) Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome. British Journal of Haematology 150:5, 529-542
CrossRef43
Chih-Kang Chiang, Reiko Inagi. (2010) Glomerular diseases: genetic causes and future therapeutics. Nature Reviews Nephrology 6:9, 539-554
CrossRef44
David Kavanagh, Timothy HJ Goodship. (2010) Atypical hemolytic uremic syndrome. Current Opinion in Hematology 17:5, 432-438
CrossRef45
R. Silasi-Mansat, H. Zhu, N. I. Popescu, G. Peer, G. Sfyroera, P. Magotti, L. Ivanciu, C. Lupu, T. E. Mollnes, F. B. Taylor, G. Kinasewitz, J. D. Lambris, F. Lupu. (2010) Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116:6, 1002-1010
CrossRef46
Peter F Zipfel, Stefan Heinen, Christine Skerka. (2010) Thrombotic microangiopathies: new insights and new challenges. Current Opinion in Nephrology and Hypertension 19:4, 372-378
CrossRef47
Marina Noris, Giuseppe Remuzzi. (2010) Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Seminars in Nephrology 30:4, 395-408
CrossRef48
Diogo Bento, Joana Mapril, Carla Rocha, Kevin J. Marchbank, David Kavanagh, Dawn Barge, Lisa Strain, Timothy H.J. Goodship, Carlos Meneses-Oliveira. (2010) Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1). Renal Failure 32:6, 753-756
CrossRef49
M. Noris, G. Remuzzi. (2010) Thrombotic Microangiopathy After Kidney Transplantation. American Journal of Transplantation 10:7, 1517-1523
CrossRef50
D. Westra, E. Volokhina, E. van der Heijden, A. Vos, M. Huigen, J. Jansen, E. van Kaauwen, T. van der Velden, N. van de Kar, L. van den Heuvel. (2010) Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrology Dialysis Transplantation 25:7, 2195-2202
CrossRef51
M. E. Starr, J. Ueda, H. Takahashi, H. Weiler, C. T. Esmon, B. M. Evers, H. Saito. (2010) Age-dependent vulnerability to endotoxemia is associated with reduction of anticoagulant factors activated protein C and thrombomodulin. Blood 115:23, 4886-4893
CrossRef52
M. Sallee, L. Daniel, M. D. Piercecchi, D. Jaubert, V. Fremeaux-Bacchi, Y. Berland, S. Burtey. (2010) Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrology Dialysis Transplantation 25:6, 2028-2032
CrossRef53
Kerstin Benz, Kerstin Amann. (2010) Thrombotic microangiopathy: new insights. Current Opinion in Nephrology and Hypertension 19:3, 242-247
CrossRef54
Carlos Fernández-de Larrea, Frederic Cofan, Federico Oppenheimer, Josep Maria Campistol, Gines Escolar, Miguel Lozano. (2010) Efficacy of Eculizumab in the Treatment of Recurrent Atypical Hemolytic-Uremic Syndrome After Renal Transplantation. Transplantation 89:7, 903-904
CrossRef55
Han-Mou Tsai. (2010) Excessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time?. Kidney International 77:4, 267-269
CrossRef56
Frank Bienaime, Marie-Agnes Dragon-Durey, Catherine H Regnier, Sara C Nilsson, Wing H Kwan, Jacques Blouin, Mathieu Jablonski, Nicolas Renault, Marie-Anne Rameix-Welti, Chantal Loirat, Catherine Sautés-Fridman, Bruno O Villoutreix, Anna M Blom, Veronique Fremeaux-Bacchi. (2010) Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney International 77:4, 339-349
CrossRef57
Hartmut Weiler. (2010) Regulation of inflammation by the protein C system. Critical Care Medicine 38, S18-S25
CrossRef58
Maren Sullivan, Zoran Erlic, Michael M. Hoffmann, Klaus Arbeiter, Ludwig Patzer, Klemens Budde, Bernd Hoppe, Martin Zeier, Karl Lhotta, Lisa A. Rybicki, Andreas Bock, Gani Berisha, Hartmut PH Neumann. (2010) Epidemiological Approach to Identifying Genetic Predispositions for Atypical Hemolytic Uremic Syndrome. Annals of Human Genetics 74:1, 17-26
CrossRef59
Len Verbeke, Michel Delforge, Daan Dierickx. (2010) Current insight into thrombotic thrombocytopenic purpura. Blood Coagulation & Fibrinolysis 21:1, 3-10
CrossRef60
Zbigniew M. Szczepiorkowski, Jeffrey L. Winters, Nicholas Bandarenko, Haewon C. Kim, Michael L. Linenberger, Marisa B. Marques, Ravindra Sarode, Joseph Schwartz, Robert Weinstein, Beth H. Shaz. (2010) Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-based approach from the apheresis applications committee of the American Society for Apheresis. Journal of Clinical Apheresis 25:3, 83-177
CrossRef61
Han-Mou Tsai. (2010) Pathophysiology of thrombotic thrombocytopenic purpura. International Journal of Hematology 91:1, 1-19
CrossRef62
(2009) In brief. Nature Reviews Nephrology 5:11, 610-610
CrossRef63
Noris, Marina, Remuzzi, Giuseppe, . (2009) Atypical Hemolytic–Uremic Syndrome. New England Journal of Medicine 361:17, 1676-1687
Full Text64
(2009) Thrombomodulin in Atypical Hemolytic–Uremic Syndrome. New England Journal of Medicine 361:15, 1511-1511
Full Text65
E. M. Conway. (2009) Super factor B-gets atypical HUS. Blood 114:13, 2572-2574
CrossRef
- Letters
